Oseltamivir Is Adequately Absorbed Following Nasogastric Administration to Adult Patients with Severe H5N1 Influenza
Walter RJ Taylor, Bui Nghia Thinh, Giang Thuc Anh, Peter Horby, Heiman Wertheim, Niklas Lindegardh, Menno D de Jong, Kasia Stepniewska, Tran Thuy Hanh, Nguyen Duc Hien, Ngo Minh Bien, Ngo Quy Chau, Annette Fox, Nghiem My Ngoc, Martin Crusat, Jeremy J Farrar, Nicholas J White, Nguyen Hong Ha, Trinh Thi Lien, Nguyen Vu Trung Show all
PLoS One | PUBLIC LIBRARY SCIENCE | Published : 2008
In the absence of a parenteral drug, oral oseltamivir is currently recommended by the WHO for treating H5N1 influenza. Whether oseltamivir absorption is adequate in severe influenza is unknown. We measured the steady state, plasma concentrations of nasogastrically administered oseltamivir 150 mg bid and its active metabolite, oseltamivir carboxylate (OC), in three, mechanically ventilated patients with severe H5N1 (male, 30 yrs; pregnant female, 22 yrs) and severe H3N2 (female, 76 yrs). Treatments were started 6, 7 and 8 days after illness onset, respectively. Both females were sampled while on continuous venovenous haemofiltration. Admission and follow up specimens (trachea, nose, throat, r..View full abstract
The South East Asian Influenza Clinical Research Network. The sponsor had no role in any aspects of this study.